Glenmark

Top-line results from a Phase 3 clinical trial of Favipiravir in mild to moderate COVID-19 patients have been announced by Glenmark Pharmaceuticals Limited. The trial was conducted across seven clinical sites in India. The open-label randomized, multicenter clinical trial, conducted in 150 patients, evaluated the efficacy and safety of Favipiravir plus standard supportive care (Favipiravir treatment arm), versus standard supportive care alone (control arm), in mild to moderate patients, randomized within a 48 hour window of testing RT-PCR positive for COVID-19. Glenmark’s Favipiravir was well tolerated with no serious adverse events (SAEs) or deaths in the Favipiravir treated arm. 69.8%…

 Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, launched the world’s first hypertension awareness symbol, in collaboration with Association of Physicians of India (API) and Hypertension Society of India (HSI). The symbol is developed in consultation with 50,000 leading doctors in the country, to raise awareness of the growing burden of hypertension and the need for timely screening. Glenmark has also pledged on-ground support to the cause, by committing to screen 5 million people for hypertension, through screening kiosks at corporate hospitals in all major metro cities. Further, a dedicated task force of 200 people has been set up to…